Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with relapsed/refractory hematological malignancies.

Trial Details

NCT ID
NCT05528887
Phase
PHASE1
Sponsor
The Affiliated People's Hospital of Ningbo University
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Autologous CAR-T cells
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Ningbo, Zhejiang, China|29.87819,121.54945

Key Eligibility Criteria

  • Histological diagnosis of hematological malignancies (such as lymphoma, myeloma, leukemia) refractory to, or relapsing after standard therapy.
  • Positive expression of specific antigens.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0\~2.
  • Adequate organ functions:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →